- Your queries
- Contact us
Illuminating how chemicals affect human health.
N-((3S)-1-azabicyclo(2.2.2)oct-3-yl)-1H-indazole-3-carboxamide hydrochlorideThese pathways are enriched significantly among genes that interact with N-((3S)-1-azabicyclo(2.2.2)oct-3-yl)-1H-indazole-3-carboxamide hydrochloride. We show only terms with a corrected p-value <0.01.
| Pathway | Pathway ID | P-value | Corrected P-value | Annotated Genes | Genome Frequency | |
|---|---|---|---|---|---|---|
| 1. | p53 signaling pathway | KEGG:hsa04115 | 1.14e-10 | 5.89e-8 | 6 | 69/42493 genes: 0.16% |
| 2. | Metabolism of xenobiotics by cytochrome P450 | KEGG:hsa00980 | 1.61e-10 | 8.34e-8 | 6 | 73/42493 genes: 0.17% |
| 3. | Metabolism | REACT:R-HSA-1430728 | 3.23e-10 | 1.67e-7 | 16 | 2172/42493 genes: 5.11% |
| 4. | Cell Cycle | REACT:R-HSA-1640170 | 8.33e-10 | 4.31e-7 | 10 | 621/42493 genes: 1.46% |
| 5. | Biological oxidations | REACT:R-HSA-211859 | 3.82e-9 | 1.98e-6 | 7 | 223/42493 genes: 0.52% |
| 6. | Steroid hormone biosynthesis | KEGG:hsa00140 | 4.65e-9 | 2.41e-6 | 5 | 58/42493 genes: 0.14% |
| 7. | Platinum drug resistance | KEGG:hsa01524 | 1.51e-8 | 7.81e-6 | 5 | 73/42493 genes: 0.17% |
| 8. | Chemical carcinogenesis | KEGG:hsa05204 | 2.72e-8 | 1.41e-5 | 5 | 82/42493 genes: 0.19% |
| 9. | Cell Cycle, Mitotic | REACT:R-HSA-69278 | 6.32e-8 | 3.27e-5 | 8 | 514/42493 genes: 1.21% |
| 10. | Metabolism of lipids and lipoproteins | REACT:R-HSA-556833 | 1.59e-7 | 8.23e-5 | 9 | 814/42493 genes: 1.92% |
| 11. | TP53 Regulates Transcription of Cell Cycle Genes | REACT:R-HSA-6791312 | 2.24e-7 | 1.16e-4 | 4 | 49/42493 genes: 0.12% |
| 12. | Metabolic pathways | KEGG:hsa01100 | 6.76e-7 | 3.50e-4 | 10 | 1270/42493 genes: 2.99% |
| 13. | TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | REACT:R-HSA-6804114 | 1.06e-6 | 5.50e-4 | 3 | 19/42493 genes: 0.04% |
| 14. | G2/M Transition | REACT:R-HSA-69275 | 1.45e-6 | 7.51e-4 | 5 | 182/42493 genes: 0.43% |
| 15. | Mitotic G2-G2/M phases | REACT:R-HSA-453274 | 1.53e-6 | 7.93e-4 | 5 | 184/42493 genes: 0.43% |
| 16. | Transcriptional Regulation by TP53 | REACT:R-HSA-3700989 | 2.56e-6 | 0.00133 | 6 | 370/42493 genes: 0.87% |
| 17. | PI3K/AKT Signaling in Cancer | REACT:R-HSA-2219528 | 2.62e-6 | 0.00136 | 4 | 90/42493 genes: 0.21% |
| 18. | Endocrine resistance | KEGG:hsa01522 | 3.26e-6 | 0.00169 | 4 | 95/42493 genes: 0.22% |
| 19. | Generic Transcription Pathway | REACT:R-HSA-212436 | 3.38e-6 | 0.00175 | 8 | 873/42493 genes: 2.05% |
| 20. | Phase 1 - Functionalization of compounds | REACT:R-HSA-211945 | 5.63e-6 | 0.00292 | 4 | 109/42493 genes: 0.26% |
| 21. | PIP3 activates AKT signaling | REACT:R-HSA-1257604 | 9.68e-6 | 0.00502 | 4 | 125/42493 genes: 0.29% |
| 22. | GAB1 signalosome | REACT:R-HSA-180292 | 1.06e-5 | 0.00551 | 4 | 128/42493 genes: 0.30% |
| 23. | PI3K/AKT activation | REACT:R-HSA-198203 | 1.06e-5 | 0.00551 | 4 | 128/42493 genes: 0.30% |
| 24. | FoxO signaling pathway | KEGG:hsa04068 | 1.20e-5 | 0.00622 | 4 | 132/42493 genes: 0.31% |
| 25. | Role of LAT2/NTAL/LAB on calcium mobilization | REACT:R-HSA-2730905 | 1.39e-5 | 0.00720 | 4 | 137/42493 genes: 0.32% |
| 26. | Apoptosis | KEGG:hsa04210 | 1.43e-5 | 0.00741 | 4 | 138/42493 genes: 0.32% |
| 27. | Mitotic G1-G1/S phases | REACT:R-HSA-453279 | 1.65e-5 | 0.00852 | 4 | 143/42493 genes: 0.34% |
| 28. | Hepatitis B | KEGG:hsa05161 | 1.69e-5 | 0.00876 | 4 | 144/42493 genes: 0.34% |
| 29. | Gene Expression | REACT:R-HSA-74160 | 1.72e-5 | 0.00893 | 10 | 1831/42493 genes: 4.31% |
| 30. | BMAL1:CLOCK,NPAS2 activates circadian gene expression | REACT:R-HSA-1368108 | 1.86e-5 | 0.00962 | 3 | 48/42493 genes: 0.11% |